Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM9LRKB)

• Drug Name: Nicotinamide-Adenine-Dinucleotide Drug Info
• Synonyms: NICOTINAMIDE-ADENINE-DINUCLEOTIDE (ACIDIC FORM); AC1NRCGS; [[(2R,3S,4R,5R)-5-(6-amino-7H-purin-9-ium-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-oxidophosphoryl] [(2R,3S,4R,5R)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphate
• Cross-matching ID:
  PubChem CID: 5892
  ChEBI ID: CHEMBL44215
  CAS Number: CAS 53-84-9
  TTD Drug ID: DM9LRKB

Molecule-Related Drug Atlas

Drug(s) Targeting Entamoeba Alcohol dehydrogenase 2 (Entamo ADH2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
2'-Monophosphoadenosine 5'-Diphosphoribose	DME9S8M	Discovery agent	N.A.	Investigative	[1]
3,5-dichlorosalicylic acid	DMQ45WH	Discovery agent	N.A.	Investigative	[11]
Cyclopropyl	DMGFEPJ	Discovery agent	N.A.	Investigative	[12]
Trifluoroethanol	DMAWTUL	Discovery agent	N.A.	Investigative	[13]
Cyclobutyl	DM35PIJ	Discovery agent	N.A.	Investigative	[12]

Drug(s) Targeting Bacterial Flavohemoglobin (Bact hmp)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Flavin-Adenine Dinucleotide	DM5S4GK	Discovery agent	N.A.	Investigative	[1]
Heme	DMGC287	Discovery agent	N.A.	Investigative	[14]
2-(N-Morpholino)-Ethanesulfonic Acid	DMZVHSB	Discovery agent	N.A.	Investigative	[1]

Drug(s) Targeting Glutathione reductase (GR)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Oxidized glutathione	DM9EQC0	Breast cancer	2C60-2C65	Approved	[15]
Golden phosphorous acetyletic compound 2	DMYJ15A	N. A.	N. A.	Patented	[16]
Terpyridineplatinum(II) complexe 3	DM54EFD	N. A.	N. A.	Patented	[16]
Terpyridineplatinum(II) complexe 4	DMOV86T	N. A.	N. A.	Patented	[16]
Golden phosphorous acetyletic compound 1	DMVAKUI	N. A.	N. A.	Patented	[16]
Acyl oxymethyl acrylamide ester derivative 1	DMXTUE1	N. A.	N. A.	Patented	[16]
Flavin-Adenine Dinucleotide	DM5S4GK	Discovery agent	N.A.	Investigative	[1]
3-Sulfinoalanine	DMILTRN	N. A.	N. A.	Investigative	[1]
1-(2'-chlorophenyl)penta-1,4-dien-3-one	DMKTZSY	Discovery agent	N.A.	Investigative	[17]
Trans-(R(S))-2-Hydroxy-1-phenylethyl nitrate	DMXC98D	Discovery agent	N.A.	Investigative	[18]

Drug(s) Targeting Biliverdin reductase A (BLVRA)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Ursodeoxycholic acid	DMCUT21	Cholelithiasis	DC11	Approved	[19]

Drug(s) Targeting Estradiol 17 beta-dehydrogenase 1 (17-beta-HSD1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
NARINGENIN	DMHAZLM	N. A.	N. A.	Phase 1	[20]
2'-Monophosphoadenosine 5'-Diphosphoribose	DME9S8M	Discovery agent	N.A.	Investigative	[1]
APIGENIN	DMI3491	Discovery agent	N.A.	Investigative	[20]
KAEMPFEROL	DMHEMUB	Discovery agent	N.A.	Investigative	[20]
4-ANDROSTENE-3-17-DIONE	DMSE8NU	Discovery agent	N.A.	Investigative	[1]
6-(3-Hydroxy-phenyl)-naphthalen-2-ol	DMH8WA2	Discovery agent	N.A.	Investigative	[21]
7-(3-Hydroxy-phenyl)-naphthalen-2-ol	DM2I91C	Discovery agent	N.A.	Investigative	[22]
NSC-94258	DM6VY3P	Discovery agent	N.A.	Investigative	[20]
4-[5-(3-Hydroxyphenyl)-3-thienyl]-2-methylphenol	DM7ERYJ	Discovery agent	N.A.	Investigative	[23]
6-(4-Hydroxy-phenyl)-naphthalen-1-ol	DM2V9XI	Discovery agent	N.A.	Investigative	[22]

Drug(s) Targeting Mitochondrial aldehyde dehydrogenase (ALDH2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
ALD-401	DM2U530	Cerebrovascular ischaemia	8B1Z	Phase 2	[24]
GS-6637	DMXG3T1	Substance use disorder	6C4Z	Phase 1	[25]
ANS-6637	DM39QWN	Substance use disorder	6C4Z	Phase 1	[26]
FP-045	DMV9FTH	Cardiovascular disease	BA00-BE2Z	Phase 1	[27]
Daidzin	DMFCMPS	N. A.	N. A.	Terminated	[1]
crotylaldehyde	DMTWRQI	Discovery agent	N.A.	Investigative	[1]
ISOFORMONENTIN	DM5CMA8	Discovery agent	N.A.	Investigative	[28]
prunetin	DMPD41Q	Discovery agent	N.A.	Investigative	[28]
CVT-10216	DMDH6PJ	Alcohol dependence	6C40.2	Investigative	[29]

Drug(s) Targeting HMG-CoA reductase (HMGCR)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Pravastatin	DM6A0X7	Adult acute monocytic leukemia		Approved	[30]
Atorvastatin	DMF28YC	Acute coronary syndrome	BA41	Approved	[31]
Cerivastatin	DMXCM7H	Hyperlipidaemia	5C80	Approved	[32]
PITAVASTATIN CALCIUM	DM1UJO0	Dyslipidemia	5C80-5C81	Approved	[33]
Rosuvastatin	DMMIQ7G	Arteriosclerosis	BD40	Approved	[34]
Fluvastatin	DM4MDJY	Arteriosclerosis	BD40	Approved	[31]
Aspirin	DM672AH	Acute coronary syndrome	BA41	Approved	[35]
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[31]
Lovastatin	DM9OZWQ	Arteriosclerosis	BD40	Approved	[36]
Teriflunomide	DMQ2FKJ	Hyperlipidaemia	5C80	Approved	[35]

Drug(s) Targeting Plasmodium Enoyl-ACP reductase (Malaria fabI)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Triclosan	DMZUR4N	Malaria	1F40-1F45	Approved	[37]
Epigallocatechin gallate	DMCGWBJ	Hepatic fibrosis	DB93.0	Phase 3	[38]
Beta-D-Glucose	DM5IHYP	Discovery agent	N.A.	Investigative	[1]
MORIN	DM2OGZ5	Discovery agent	N.A.	Investigative	[39]
3,7,3',4'-TETRAHYDROXYFLAVONE	DMES906	Discovery agent	N.A.	Investigative	[39]
(-)-CATECHINGALLATE	DMZOGSK	Discovery agent	N.A.	Investigative	[39]
Thiolactomycin	DMBAWDG	Malaria	1F40-1F45	Investigative	[37]
GALLOCATECHIN GALLATE	DMX2084	Discovery agent	N.A.	Investigative	[39]
Diazaborines	DM5UFZX	Discovery agent	N.A.	Investigative	[40]
ISORHAMNETIN	DMQ4Z6E	Discovery agent	N.A.	Investigative	[39]

Drug(s) Targeting Estradiol 17 beta-dehydrogenase 4 (HSD17B4)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
3r-Hydroxydecanoyl-Coa	DMV1HMX	Discovery agent	N.A.	Investigative	[13]

Drug(s) Targeting Sorbitoldehydrogenase (SORD)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
CP-470,711	DMS2RHE	Discovery agent	N.A.	Investigative	[41]

Drug(s) Targeting Alpha-glucosidase (GLA)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cipaglucosidase alfa	DMAPDH2	Glycogen storage disease type II	5C51.3	Approved in EU	[42]
Cipaglucosidase alfa	DMAPDH2	Glycogen storage disease type II	5C51.3	Approved in EU	[43]
Deoxynojirimycin	DM2ATZB	Pompe disease	5C51.3	Phase 3	[44]
Anamorelin	DM6HXTS	Carbohydrate metabolism disorder	5C51.Z	Phase 3	[45]
Maltose	DMH0ROP	N. A.	N. A.	Phase 1/2	[13]
AAV2/8-LSPhGAA	DMIX5HF	Pompe disease	5C51.3	Phase 1	[46]
Beta-D-Glucose	DM5IHYP	Discovery agent	N.A.	Investigative	[1]
Double Oxidized Cysteine	DM6TU84	Discovery agent	N.A.	Investigative	[1]
POP-1	DMVTKCX	Solid tumour/cancer	2A00-2F9Z	Investigative	[47]
JBP-1	DM0KMPN	Solid tumour/cancer	2A00-2F9Z	Investigative	[47]

Drug(s) Targeting Deoxyhypusine synthase (DHPS)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
1-Guanidinium-7-Aminoheptane	DM42IY7	Discovery agent	N.A.	Investigative	[1]
N-guanyl-1,7-diaminoheptane	DMBG3ZF	Discovery agent	N.A.	Investigative	[48]
N1-guanyl-1,7-diaminoheptane	DMXE8CB	Discovery agent	N.A.	Investigative	[49]

Drug(s) Targeting Adenosylhomocysteinase (AHCY)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
ARISTEROMYCIN	DMRXB74	N. A.	N. A.	Terminated	[50]
2-Propanol, Isopropanol	DML5O0H	Discovery agent	N.A.	Investigative	[14]
Neplanocin A	DMXULGK	Discovery agent	N.A.	Investigative	[51]
5'-deoxy-5'-ureidoadenosine	DM8IQX4	Discovery agent	N.A.	Investigative	[52]
5(E)-(5'-Deoxyadenosin-5'-ylidene)pentanoic acid	DM1IGOD	Discovery agent	N.A.	Investigative	[53]
5-methylenearisteromycin	DMIQ1X3	Discovery agent	N.A.	Investigative	[50]
NORARISTEROMYCIN	DMZ9024	Discovery agent	N.A.	Investigative	[54]
D-Eritadenine	DM2XT7S	N. A.	N. A.	Investigative	[1]
5'-S-ethyl-5'-thioadenosine	DM0PQH1	Discovery agent	N.A.	Investigative	[14]
FLUORO-NEPLANOCIN A	DM0LR7G	Discovery agent	N.A.	Investigative	[55]

Drug(s) Targeting Bacterial Fatty acid synthetase I (Bact inhA)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Isoniazid	DM5JVS3	Latent tuberculosis infection		Approved	[56]
Pyrazinamide	DM4IF32	Meningeal tuberculosis		Approved	[57]
Ethionamide	DM8K3EI	Pulmonary tuberculosis	1B10.Z	Approved	[58]
Prothionamide	DMX0EZJ	Tuberculosis	1B10-1B1Z	Approved	[58]
AFN-1720	DM6AJKC	Bacterial infection	1A00-1C4Z	Phase 2	[59]
MMV00/0053	DMF27BS	Malaria	1F40-1F45	Terminated	[60]
Beta-D-Glucose	DM5IHYP	Discovery agent	N.A.	Investigative	[1]
2-Hexadecynoic acid	DMTFIPZ	Discovery agent	N.A.	Investigative	[61]
4-(2-Thienyl)-1-(4-Methylbenzyl)-1h-Imidazole	DMX681M	Discovery agent	N.A.	Investigative	[1]
Indole Naphthyridinone	DMB4ZNW	Discovery agent	N.A.	Investigative	[1]

Drug(s) Targeting Trypanosoma Dihydrolipoamide dehydrogenase (Trypano LPD)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Flavin-Adenine Dinucleotide	DM5S4GK	Discovery agent	N.A.	Investigative	[1]

Drug(s) Targeting Bacterial NH(3)-dependent NAD(+) synthetase (Bact nadE)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Pyrophosphate 2-	DMZQ75M	Discovery agent	N.A.	Investigative	[14]
[3H]alphabeta-meATP	DMWV5C3	Discovery agent	N.A.	Investigative	[1]
Diphosphate	DMHY30B	Discovery agent	N.A.	Investigative	[1]

Drug(s) Targeting Bacterial Dehydroquinate synthase (Bact aroB)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Carbaphosphonate	DMGFLI7	Discovery agent	N.A.	Investigative	[1]

Drug(s) Targeting L-lactate dehydrogenase (LDH)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
OXAMATE	DMTYBC9	Discovery agent	N.A.	Investigative	[1]
3,7-DIHYDROXYNAPHTHALENE-2-CARBOXYLIC ACID	DMJ0654	Discovery agent	N.A.	Investigative	[13]
4-Hydroxy-1,2,5-Oxadiazole-3-Carboxylic Acid	DM6WJ4K	Discovery agent	N.A.	Investigative	[1]
3-Hydroxyisoxazole-4-Carboxylic Acid	DMKLZXV	Discovery agent	N.A.	Investigative	[1]
Naphthalene-2,6-disulfonic acid	DMLHWNG	Discovery agent	N.A.	Investigative	[14]
4-Hydroxy-1,2,5-Thiadiazole-3-Carboxylic Acid	DME29PX	Discovery agent	N.A.	Investigative	[1]

Drug(s) Targeting Bacterial Nicotinate-nucleotide adenylyltransferase (Bact nadD)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
DZ9	DM2HLGC	N. A.	N. A.	Patented	[62]
AC1LJNG0	DM9Q0EC	N. A.	N. A.	Patented	[62]
STK696827	DM19GAY	N. A.	N. A.	Patented	[62]
Deamido-NAD	DMDFRTI	N. A.	N. A.	Investigative	[63]

Drug(s) Targeting Inosine-5'-monophosphate dehydrogenase 2 (IMPDH2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Mycophenolate mofetil	DMPQAGE	Hepatosplenic T-cell lymphoma		Approved	[64]
Urea and carbamate bioisostere derivative 1	DMEQFXZ	N. A.	N. A.	Patented	[65]
Inosinic Acid	DMLR86H	Discovery agent	N.A.	Investigative	[1]
Mycophenolic hydroxamic acid	DM4YRAH	Discovery agent	N.A.	Investigative	[66]
Tiazofurin adenine dinucleotide	DMEFVPH	Discovery agent	N.A.	Investigative	[67]
Mycophenolic bis(sulfonamide)	DMUQP3J	Discovery agent	N.A.	Investigative	[68]
6-Chloropurine Riboside, 5'-Monophosphate	DMWB43U	Discovery agent	N.A.	Investigative	[1]
1-methyl-1H-indole-3-carboxamide	DMUKAH6	Discovery agent	N.A.	Investigative	[69]
6-phenyl-3-(pyridin-4-yl)-1H-indole	DM3UBR5	Discovery agent	N.A.	Investigative	[70]
C4-MAD	DMGA9U7	Discovery agent	N.A.	Investigative	[71]

Drug(s) Targeting Intestinal maltase-glucoamylase (MGAM)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Voglibose	DMUBP9O	Diabetic complication	5A2Y	Approved	[72]
Acarbose	DMRM3AW	Diabetic complication	5A2Y	Approved	[73]
Miglitol	DMXBQAM	Diabetic complication	5A2Y	Approved	[74]
Rh-alphaglucosidase	DMNF0G8	Pompe disease	5C51.3	Approved	[75]
Deoxynojirimycin	DM2ATZB	Pompe disease	5C51.3	Phase 3	[44]
Alpha-glucosidase	DM2RTGP	Muscle disease	FB3Z	Phase 3	[76]
PAZ-320	DMU0812	Type-2 diabetes	5A11	Phase 2	[77]
SC-49483	DM180VX	Acquired immune deficiency syndrome	1C62.3	Phase 2	[78]
Maltose	DMH0ROP	N. A.	N. A.	Phase 1/2	[13]
SALACINOL	DMVKQT8	N. A.	N. A.	Phase 1/2	[79]

Drug(s) Targeting UDP-glucose 4-epimerase (GALE)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
PSAMMAPLIN A	DM6T0IQ	Discovery agent	N.A.	Investigative	[80]
UDP-glucose	DMLT4JA	Discovery agent	N.A.	Investigative	[1]
Uridine Diphosphate Galactose	DMPA0BJ	Discovery agent	N.A.	Investigative	[81]
Uridine-Diphosphate-N-Acetylgalactosamine	DMXHO6J	N. A.	N. A.	Investigative	[1]
Uridine-Diphosphate-N-Acetylglucosamine	DMEQSTP	Discovery agent	N.A.	Investigative	[13]
Tetramethylammonium Ion	DMLEPYN	Discovery agent	N.A.	Investigative	[1]
Uridine-5'-Diphosphate	DMDQKJB	Discovery agent	N.A.	Investigative	[1]
Phenyl-Uridine-5'-Diphosphate	DM7J0YG	Discovery agent	N.A.	Investigative	[1]
Uridine-5'-Diphosphate-Mannose	DMAYCQU	Discovery agent	N.A.	Investigative	[1]

Drug(s) Affected By NAD kinase (NADK)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Quercetin	DM3NC4M	Obesity	5B81	Approved	[82]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[83]
Isotretinoin	DM4QTBN	Acne vulgaris	ED80	Approved	[84]
Acetic Acid, Glacial	DM4SJ5Y	infection in the ear canal	AA0Y	Approved	[85]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[86]
Motexafin gadolinium	DMEJKRF	Brain cancer	2A00	Approved	[85]
Bortezomib	DMNO38U	Leukemia		Approved	[87]
Arsenic	DMTL2Y1	N. A.	N. A.	Approved	[88]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[89]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[90]

Drug(s) Affected By Mucin-2 (MUC2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[91]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[92]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[93]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[94]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[95]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[86]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[96]
Amphotericin B	DMTAJQE	Acne vulgaris	ED80	Approved	[97]
Arsenic	DMTL2Y1	N. A.	N. A.	Approved	[98]
DTI-015	DMXZRW0	Brain cancer	2A00	Approved	[99]

Drug(s) Affected By Polypeptide N-acetylgalactosaminyltransferase 1 (GALNT1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Selenium	DM25CGV	N. A.	N. A.	Approved	[100]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[92]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[101]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[102]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[103]
Carbamazepine	DMZOLBI	Epilepsy	8A60-8A68	Approved	[102]
Topotecan	DMP6G8T	Central nervous system neoplasm		Approved	[104]
Tocopherol	DMBIJZ6	N. A.	N. A.	Phase 2	[100]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[105]
Nicotinamide mononucleotide	DMW1LKP	N. A.	N. A.	Preclinical	[6]

Drug(s) Affected By Epidermal retinol dehydrogenase 2 (SDR16C5)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[106]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[107]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[101]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[108]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[109]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[110]
Vitamin A	DMJ2AH4	Night blindness	9D45	Approved	[106]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[111]
Milchsaure	DM462BT	Pruritus	EC90	Investigative	[112]
Trichostatin A	DM9C8NX	Solid tumour/cancer	2A00-2F9Z	Investigative	[108]

Drug(s) Affected By Chimeric ERCC6-PGBD3 protein (ERCC6)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[113]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[86]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[109]
Decitabine	DMQL8XJ	Acute myelogenous leukaemia	2A41	Approved	[114]
Arsenic	DMTL2Y1	N. A.	N. A.	Approved	[115]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[114]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[90]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[116]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[117]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[118]

Drug(s) Affected By Poly polymerase 1 (PARP1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[119]
Gefitinib	DM15F0X	Colon adenocarcinoma		Approved	[120]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[121]
Nitric Oxide	DM1RBYG	Hypertension	BA00-BA04	Approved	[122]
Citalopram	DM2G9AE	Acute coronary syndrome	BA41	Approved	[123]
Ciprofloxacin XR	DM2NLS9	Acute gonococcal cervicitis		Approved	[124]
Imipramine	DM2NUH3	Depression	6A70-6A7Z	Approved	[123]
Colchicine	DM2POTE	Acute gout flare	FA25.0	Approved	[125]
Sulindac	DM2QHZU	Acute myelogenous leukaemia	2A41	Approved	[126]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[127]

Drug(s) Affected By Protein mono-ADP-ribosyltransferase PARP10 (PARP10)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[83]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[86]
Temozolomide	DMKECZD	Adenocarcinoma	2D40	Approved	[128]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[129]
Arsenic	DMTL2Y1	N. A.	N. A.	Approved	[130]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[131]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[132]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[90]
Triclosan	DMZUR4N	Malaria	1F40-1F45	Approved	[133]
(+)-JQ1	DM1CZSJ	Testicular cancer	2C80	Phase 1	[134]

Drug(s) Affected By Hydroxyacyl-coenzyme A dehydrogenase, mitochondrial (HADH)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[83]
Isotretinoin	DM4QTBN	Acne vulgaris	ED80	Approved	[84]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[135]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[136]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[101]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[137]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[138]
Fenofibrate	DMFKXDY	Coronary atherosclerosis		Approved	[139]
Niclosamide	DMJAGXQ	Cestodes infection	1F70-1F76	Approved	[140]
Temozolomide	DMKECZD	Adenocarcinoma	2D40	Approved	[128]

Drug(s) Affected By Aldehyde dehydrogenase, mitochondrial (ALDH2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[141]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[142]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[83]
Cyclophosphamide	DM4O2Z7	Advanced cancer	2A00-2F9Z	Approved	[143]
Hydroquinone	DM6AVR4	Melasma	ED60.1	Approved	[144]
Imatinib	DM7RJXL	Acute lymphoblastic leukaemia	2A85	Approved	[145]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[101]
Disulfiram	DMCL2OK	Alcohol dependence	6C40.2	Approved	[146]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[137]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[138]

Drug(s) Affected By NADH-cytochrome b5 reductase 3 (CYB5R3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[147]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[148]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[135]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[101]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[86]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[138]
Zoledronate	DMIXC7G	Adenocarcinoma	2D40	Approved	[87]
Temozolomide	DMKECZD	Adenocarcinoma	2D40	Approved	[128]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[109]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[149]

Drug(s) Affected By Protein DEK (DEK)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Quercetin	DM3NC4M	Obesity	5B81	Approved	[142]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[150]
Aspirin	DM672AH	Acute coronary syndrome	BA41	Approved	[151]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[152]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[152]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[95]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[153]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[138]
Folic Acid	DMEMBJC	Colorectal carcinoma		Approved	[154]
Temozolomide	DMKECZD	Adenocarcinoma	2D40	Approved	[128]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Adenosylhomocysteinase (AHCY)	TTE2KUJ	SAHH_HUMAN	Inhibitor	[1]
Alpha-glucosidase (GLA)	TTHCF4J	LYAG_HUMAN; GANAB_HUMAN; GANC_HUMAN	Inhibitor	[1]
Bacterial Dehydroquinate synthase (Bact aroB)	TTPS7KA	AROB_ECOLI	Inhibitor	[1]
Bacterial Fatty acid synthetase I (Bact inhA)	TTVTX4N	INHA_MYCTU	Inhibitor	[1]
Bacterial Flavohemoglobin (Bact hmp)	TTNAW8S	HMP_ECOLI	Inhibitor	[1]
Bacterial NH(3)-dependent NAD(+) synthetase (Bact nadE)	TT8WCXO	NADE_ECOLI	Inhibitor	[1]
Bacterial Nicotinate-nucleotide adenylyltransferase (Bact nadD)	TT1NFO3	NADD_ECOLI	Inhibitor	[1]
Biliverdin reductase A (BLVRA)	TTJBPN3	BIEA_HUMAN	Inhibitor	[1]
Deoxyhypusine synthase (DHPS)	TTBO2A9	DHYS_HUMAN	Inhibitor	[1]
Entamoeba Alcohol dehydrogenase 2 (Entamo ADH2)	TTJS7O4	ADH2_ENTHI	Inhibitor	[1]
Estradiol 17 beta-dehydrogenase 1 (17-beta-HSD1)	TTIWB6L	DHB1_HUMAN	Inhibitor	[1]
Estradiol 17 beta-dehydrogenase 4 (HSD17B4)	TTL1WGS	DHB4_HUMAN	Inhibitor	[1]
Glutathione reductase (GR)	TTEP6RV	GSHR_HUMAN	Inhibitor	[1]
Haemophilus influenzae NadR protein (Hae-influ nadR)	TTWUDYC	NADR_HAEIN	Inhibitor	[1]
HMG-CoA reductase (HMGCR)	TTPADOQ	HMDH_HUMAN	Inhibitor	[1]
Inosine-5'-monophosphate dehydrogenase 2 (IMPDH2)	TTTB4UP	IMDH2_HUMAN	Inhibitor	[1]
Intestinal maltase-glucoamylase (MGAM)	TTXWASR	MGA_HUMAN	Inhibitor	[1]
L-lactate dehydrogenase (LDH)	TTAZHU0	LDHA_HUMAN; LDHB_HUMAN; LDHC_HUMAN	Inhibitor	[1]
Mitochondrial aldehyde dehydrogenase (ALDH2)	TTFLN4T	ALDH2_HUMAN	Inhibitor	[1]
Plasmodium Enoyl-ACP reductase (Malaria fabI)	TTNX2CS	Q965D5_PLAFA	Inhibitor	[1]
Pseudomonas Nicotinate-nucleotide adenylyltransferase (Pseudo nadD)	TTKVNRF	NADD_PSEAE	Inhibitor	[1]
Sorbitoldehydrogenase (SORD)	TTLSRBZ	DHSO_HUMAN	Inhibitor	[1]
Trypanosoma Dihydrolipoamide dehydrogenase (Trypano LPD)	TTBKQL3	DLDH_TRYCR	Inhibitor	[1]
UDP-glucose 4-epimerase (GALE)	TTGRHIB	GALE_HUMAN	Inhibitor	[1]

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
Aldehyde dehydrogenase, mitochondrial (ALDH2)	OTKJ9I3N	ALDH2_HUMAN	Drug Response	[2]
Chimeric ERCC6-PGBD3 protein (ERCC6)	OT2QZKSF	ERPG3_HUMAN	Regulation of Drug Effects	[3]
Epidermal retinol dehydrogenase 2 (SDR16C5)	OT7BJD1M	RDHE2_HUMAN	Gene/Protein Processing	[4]
Hydroxyacyl-coenzyme A dehydrogenase, mitochondrial (HADH)	OTJDOL20	HCDH_HUMAN	Regulation of Drug Effects	[5]
Mucin-2 (MUC2)	OT3X4QVX	MUC2_HUMAN	Gene/Protein Processing	[6]
NAD kinase (NADK)	OTYN9GX0	NADK_HUMAN	Post-Translational Modifications	[7]
NADH-cytochrome b5 reductase 3 (CYB5R3)	OTUGT3G8	NB5R3_HUMAN	Drug Response	[8]
Poly polymerase 1 (PARP1)	OT310QSG	PARP1_HUMAN	Regulation of Drug Effects	[9]
Polypeptide N-acetylgalactosaminyltransferase 1 (GALNT1)	OTO3RO36	GALT1_HUMAN	Gene/Protein Processing	[6]
Protein DEK (DEK)	OTYCJ5H6	DEK_HUMAN	Biotransformations	[10]

References

• [1] How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
• [2] Catalytic contribution of threonine 244 in human ALDH2. Chem Biol Interact. 2013 Feb 25;202(1-3):32-40. doi: 10.1016/j.cbi.2012.12.009. Epub 2013 Jan 4.
• [3] A high-fat diet and NAD(+) activate Sirt1 to rescue premature aging in cockayne syndrome. Cell Metab. 2014 Nov 4;20(5):840-855. doi: 10.1016/j.cmet.2014.10.005. Epub 2014 Nov 4.
• [4] Biochemical characterization of human epidermal retinol dehydrogenase 2. Chem Biol Interact. 2009 Mar 16;178(1-3):182-7. doi: 10.1016/j.cbi.2008.09.019. Epub 2008 Sep 24.
• [5] Intrinsic alcohol dehydrogenase and hydroxysteroid dehydrogenase activities of human mitochondrial short-chain L-3-hydroxyacyl-CoA dehydrogenase. Biochem J. 2000 Jan 1;345 Pt 1(Pt 1):139-43.
• [6] Oxyresveratrol stimulates mucin production in an NAD+-dependent manner in human intestinal goblet cells. Food Chem Toxicol. 2018 Aug;118:880-888.
• [7] A second target of benzamide riboside: dihydrofolate reductase. Cancer Biol Ther. 2012 Nov;13(13):1290-8.
• [8] Expression of a novel P275L variant of NADH:cytochrome b5 reductase gives functional insight into the conserved motif important for pyridine nucleotide binding. Arch Biochem Biophys. 2006 Mar 1;447(1):59-67.
• [9] Analyzing structure-function relationships of artificial and cancer-associated PARP1 variants by reconstituting TALEN-generated HeLa PARP1 knock-out cells. Nucleic Acids Res. 2016 Dec 1;44(21):10386-10405. doi: 10.1093/nar/gkw859. Epub 2016 Sep 29.
• [10] Overexpression of the human DEK oncogene reprograms cellular metabolism and promotes glycolysis. PLoS One. 2017 May 30;12(5):e0177952. doi: 10.1371/journal.pone.0177952. eCollection 2017.
• [11] Correlation of binding constants and molecular modelling of inhibitors in the active sites of aldose reductase and aldehyde reductase. Bioorg Med Chem. 2009 Feb 1;17(3):1244-50.
• [12] Entamoeba histolytica alcohol dehydrogenase 2 (EhADH2) as a target for anti-amoebic agents. J Antimicrob Chemother. 2004 Jul;54(1):56-9.
• [13] DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Nucleic Acids Res. 2011 Jan;39(Database issue):D1035-41.
• [14] The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
• [15] The purification and properties of glutathione reductase from the cestode Moniezia expansa. Int J Biochem Cell Biol. 1995 Apr;27(4):393-401.
• [16] Thioredoxin reductase inhibitors: a patent review.Expert Opin Ther Pat. 2017 May;27(5):547-556.
• [17] Irreversible inactivation of trypanothione reductase by unsaturated Mannich bases: a divinyl ketone as key intermediate. J Med Chem. 2005 Nov 17;48(23):7400-10.
• [18] In vitro inhibition of human erythrocyte glutathione reductase by some new organic nitrates. Bioorg Med Chem Lett. 2009 Jul 1;19(13):3661-3.
• [19] Role of vitamin C transporters and biliverdin reductase in the dual pro-oxidant and anti-oxidant effect of biliary compounds on the placental-fetal... Toxicol Appl Pharmacol. 2008 Oct 15;232(2):327-36.
• [20] Discovery of nonsteroidal 17beta-hydroxysteroid dehydrogenase 1 inhibitors by pharmacophore-based screening of virtual compound libraries. J Med Chem. 2008 Jul 24;51(14):4188-99.
• [21] Substituted 6-phenyl-2-naphthols. Potent and selective nonsteroidal inhibitors of 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1): design,... J Med Chem. 2008 Aug 14;51(15):4685-98.
• [22] Design, synthesis, and biological evaluation of (hydroxyphenyl)naphthalene and -quinoline derivatives: potent and selective nonsteroidal inhibitors... J Med Chem. 2008 Apr 10;51(7):2158-69.
• [23] New insights into the SAR and binding modes of bis(hydroxyphenyl)thiophenes and -benzenes: influence of additional substituents on 17beta-hydroxyst... J Med Chem. 2009 Nov 12;52(21):6724-43.
• [24] A novel aldehyde dehydrogenase-3 activator leads to adult salivary stem cell enrichment in vivo. Clin Cancer Res. 2011 Dec 1;17(23):7265-72.
• [25] Clinical pipeline report, company report or official report of Gilead.
• [26] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [27] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [28] Structure of daidzin, a naturally occurring anti-alcohol-addiction agent, in complex with human mitochondrial aldehyde dehydrogenase. J Med Chem. 2008 Aug 14;51(15):4482-7.
• [29] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2595).
• [30] A randomized, double-blind trial comparing the efficacy and safety of pitavastatin versus pravastatin in patients with primary hypercholesterolemia. Atherosclerosis. 2002 Jun;162(2):373-9.
• [31] Equally potent inhibitors of cholesterol synthesis in human hepatocytes have distinguishable effects on different cytochrome P450 enzymes. Biopharm Drug Dispos. 2000 Dec;21(9):353-64.
• [32] Emerging therapies for multiple myeloma. Expert Opin Emerg Drugs. 2009 Mar;14(1):99-127.
• [33] Cholesterol-lowering effect of NK-104, a 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor, in guinea pig model of hyperlipidemia. Arzneimittelforschung. 2001;51(3):197-203.
• [34] New dimension of statin action on ApoB atherogenicity. Clin Cardiol. 2003 Jan;26(1 Suppl 1):I7-10.
• [35] Emerging drugs in peripheral arterial disease. Expert Opin Emerg Drugs. 2006 Mar;11(1):75-90.
• [36] Microarray and biochemical analysis of lovastatin-induced apoptosis of squamous cell carcinomas. Neoplasia. 2002 Jul-Aug;4(4):337-46.
• [37] Novel molecular targets for antimalarial drug development. Chem Biol Drug Des. 2008 Apr;71(4):287-97.
• [38] Green tea catechins potentiate triclosan binding to enoyl-ACP reductase from Plasmodium falciparum (PfENR). J Med Chem. 2007 Feb 22;50(4):765-75.
• [39] Inhibition of Plasmodium falciparum fatty acid biosynthesis: evaluation of FabG, FabZ, and FabI as drug targets for flavonoids. J Med Chem. 2006 Jun 1;49(11):3345-53.
• [40] Lipid biosynthesis as a target for antibacterial agents. Prog Lipid Res. 2001 Nov;40(6):467-97.
• [41] Sorbitol dehydrogenase: a novel target for adjunctive protection of ischemic myocardium. FASEB J. 2003 Dec;17(15):2331-3.
• [42] Cipaglucosidase Alfa: First Approval. Drugs. 2023 Jun;83(8):739-745.
• [43] FDA Approved Drug Products from FDA Official Website. 2023. Application Number: 761204
• [44] Nitrogen-in-the-ring pyranoses and furanoses: structural basis of inhibition of mammalian glycosidases. J Med Chem. 1994 Oct 28;37(22):3701-6.
• [45] Absorption, elimination, and metabolism of CS-1036, a novel -amylase inhibitor in rats and monkeys, and the relationship between gastrointestinal distribution and suppression of glucose absorption.Drug Metab Dispos.2013 Apr;41(4):878-87.
• [46] ClinicalTrials.gov (NCT03533673) AAV2/8-LSPhGAA in Late-Onset Pompe Disease. U.S. National Institutes of Health.
• [47] US patent application no. 2012,0251,516, PHARMACEUTICAL COMPOSITION FOR TREATING CANCER COMPRISING TRYPSINOGEN AND/OR CHYMOTRYPSINOGEN AND AN ACTIVE AGENT SELECTED FROM A SELENIUM COMPOUND, A VANILLOID COMPOUND AND A CYTOPLASMIC GLYCOLYSIS REDUCTION AGENT.
• [48] Modification of eukaryotic initiation factor 5A from Plasmodium vivax by a truncated deoxyhypusine synthase from Plasmodium falciparum: An enzyme w... Bioorg Med Chem. 2007 Sep 15;15(18):6200-7.
• [49] Effects of N1-guanyl-1,7-diaminoheptane, an inhibitor of deoxyhypusine synthase, on the growth of tumorigenic cell lines in culture. Biochim Biophys Acta. 1996 Jan 10;1310(1):119-26.
• [50] Synthesis of 2-modified aristeromycins and their analogs as potent inhibitors against Plasmodium falciparum S-adenosyl-L-homocysteine hydrolase. Bioorg Med Chem. 2008 Apr 1;16(7):3809-15.
• [51] Molecular approaches for the treatment of hemorrhagic fever virus infections. Antiviral Res. 1993 Sep;22(1):45-75.
• [52] Design, synthesis, and molecular modeling studies of 5'-deoxy-5'-ureidoadenosine: 5'-ureido group as multiple hydrogen bonding donor in the active ... Bioorg Med Chem Lett. 2007 Aug 15;17(16):4456-9.
• [53] Synthesis of 5'-functionalized nucleosides: S-Adenosylhomocysteine analogues with the carbon-5' and sulfur atoms replaced by a vinyl or halovinyl u... Bioorg Med Chem. 2008 May 15;16(10):5424-33.
• [54] Synthesis of 4'-modified noraristeromycins to clarify the effect of the 4'-hydroxyl groups for inhibitory activity against S-adenosyl-L-homocystein... Bioorg Med Chem Lett. 2008 Apr 15;18(8):2615-8.
• [55] Synthesis of 5'-substituted fluoro-neplanocin A analogues: importance of a hydrogen bonding donor at 5'-position for the inhibitory activity of S-a... Bioorg Med Chem Lett. 2004 Nov 15;14(22):5641-4.
• [56] Diversity in enoyl-acyl carrier protein reductases. Cell Mol Life Sci. 2009 May;66(9):1507-17.
• [57] Pyrazinamide inhibits the eukaryotic-like fatty acid synthetase I (FASI) of Mycobacterium tuberculosis. Nat Med. 2000 Sep;6(9):1043-7.
• [58] Mechanism of thioamide drug action against tuberculosis and leprosy. J Exp Med. 2007 Jan 22;204(1):73-8.
• [59] Affinium Pharmaceuticals Announces the Initiation of a Phase 1 Intravenous Clinical Trial of a New Antibiotic Prodrug, and the Closing of a Follow-on Financing Round. PR Newswire Sep. 4, 2013 10:16 PM.
• [60] SAR and pharmacophore models for the rhodanine inhibitors of Plasmodium falciparum enoyl-acyl carrier protein reductase. IUBMB Life. 2010 Mar;62(3):204-13.
• [61] 2-Hexadecynoic acid inhibits plasmodial FAS-II enzymes and arrests erythrocytic and liver stage Plasmodium infections. Bioorg Med Chem. 2010 Nov 1;18(21):7475-85.
• [62] Targeting NAD biosynthesis in bacterial pathogens. US8785499.
• [63] Crystal structures of E. coli nicotinate mononucleotide adenylyltransferase and its complex with deamido-NAD. Structure. 2002 Jan;10(1):69-79.
• [64] Clinical pipeline report, company report or official report of Roche (2009).
• [65] Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitors: a patent and scientific literature review (2002-2016).Expert Opin Ther Pat. 2017 Jun;27(6):677-690.
• [66] Structure-activity relationships for inhibition of inosine monophosphate dehydrogenase and differentiation induction of K562 cells among the mycoph... Bioorg Med Chem. 2010 Nov 15;18(22):8106-11.
• [67] Dual inhibitors of inosine monophosphate dehydrogenase and histone deacetylases for cancer treatment. J Med Chem. 2007 Dec 27;50(26):6685-91.
• [68] Bis(sulfonamide) isosters of mycophenolic adenine dinucleotide analogues: inhibition of inosine monophosphate dehydrogenase. Bioorg Med Chem. 2008 Aug 1;16(15):7462-9.
• [69] Low molecular weight indole fragments as IMPDH inhibitors. Bioorg Med Chem Lett. 2006 May 1;16(9):2535-8.
• [70] Novel indole inhibitors of IMPDH from fragments: synthesis and initial structure-activity relationships. Bioorg Med Chem Lett. 2006 May 1;16(9):2539-42.
• [71] Novel mycophenolic adenine bis(phosphonate) analogues as potential differentiation agents against human leukemia. J Med Chem. 2002 Jan 31;45(3):703-12.
• [72] Effects of changeover from voglibose to acarbose on postprandial triglycerides in type 2 diabetes mellitus patients. Adv Ther. 2009 Jun;26(6):660-6.
• [73] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [74] Drug therapy of postprandial hyperglycaemia. Drugs. 1999 Jan;57(1):19-29.
• [75] 2006 drug approvals: finding the niche. Nat Rev Drug Discov. 2007 Feb;6(2):99-101.
• [76] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2627).
• [77] Treatment With Novel Galactomannan Derivative Reduces 2-Hour Postprandial Glucose Excursions in Individuals With Type 2 Diabetes Treated With Oral Medications and/or Insulin. J Diabetes Sci Technol. 2014 September; 8(5): 1018-1022.
• [78] Pathology of perbutylated-N-butyl-1-deoxynojiromycin (an alpha-glucosidase-1 inhibitor) in Sprague-Dawley rats. Toxicol Pathol. 1996 Sep-Oct;24(5):531-8.
• [79] Probing the active-site requirements of human intestinal N-terminal maltase-glucoamylase: Synthesis and enzyme inhibitory activities of a six-membe... Bioorg Med Chem. 2010 Nov 15;18(22):7794-8.
• [80] Identification of novel inhibitors of UDP-Glc 4'-epimerase, a validated drug target for african sleeping sickness. Bioorg Med Chem Lett. 2006 Nov 15;16(22):5744-7.
• [81] Crystal structure of beta1,4-galactosyltransferase complex with UDP-Gal reveals an oligosaccharide acceptor binding site. J Mol Biol. 2002 Apr 26;318(2):491-502.
• [82] Quantitative phosphoproteomics reveal cellular responses from caffeine, coumarin and quercetin in treated HepG2 cells. Toxicol Appl Pharmacol. 2022 Aug 15;449:116110. doi: 10.1016/j.taap.2022.116110. Epub 2022 Jun 7.
• [83] Transcriptional and Metabolic Dissection of ATRA-Induced Granulocytic Differentiation in NB4 Acute Promyelocytic Leukemia Cells. Cells. 2020 Nov 5;9(11):2423. doi: 10.3390/cells9112423.
• [84] Temporal changes in gene expression in the skin of patients treated with isotretinoin provide insight into its mechanism of action. Dermatoendocrinol. 2009 May;1(3):177-87.
• [85] Motexafin gadolinium and zinc induce oxidative stress responses and apoptosis in B-cell lymphoma lines. Cancer Res. 2005 Dec 15;65(24):11676-88.
• [86] Integrative omics data analyses of repeated dose toxicity of valproic acid in vitro reveal new mechanisms of steatosis induction. Toxicology. 2018 Jan 15;393:160-170.
• [87] The proapoptotic effect of zoledronic acid is independent of either the bone microenvironment or the intrinsic resistance to bortezomib of myeloma cells and is enhanced by the combination with arsenic trioxide. Exp Hematol. 2011 Jan;39(1):55-65.
• [88] Prenatal arsenic exposure and the epigenome: identifying sites of 5-methylcytosine alterations that predict functional changes in gene expression in newborn cord blood and subsequent birth outcomes. Toxicol Sci. 2015 Jan;143(1):97-106. doi: 10.1093/toxsci/kfu210. Epub 2014 Oct 10.
• [89] Gene expression analysis of precision-cut human liver slices indicates stable expression of ADME-Tox related genes. Toxicol Appl Pharmacol. 2011 May 15;253(1):57-69.
• [90] Bringing in vitro analysis closer to in vivo: studying doxorubicin toxicity and associated mechanisms in 3D human microtissues with PBPK-based dose modelling. Toxicol Lett. 2018 Sep 15;294:184-192.
• [91] Global molecular effects of tocilizumab therapy in rheumatoid arthritis synovium. Arthritis Rheumatol. 2014 Jan;66(1):15-23.
• [92] Integrated assessment by multiple gene expression analysis of quercetin bioactivity on anticancer-related mechanisms in colon cancer cells in vitro. Eur J Nutr. 2005 Mar;44(3):143-56. doi: 10.1007/s00394-004-0503-1. Epub 2004 Apr 30.
• [93] Induction of differentiation and peroxisome proliferator-activated receptor gamma expression in colon cancer cell lines by troglitazone. J Cancer Res Clin Oncol. 2004 Feb;130(2):73-9. doi: 10.1007/s00432-003-0510-2. Epub 2003 Nov 21.
• [94] Induction of the cytochrome P450 gene CYP26 during mucous cell differentiation of normal human tracheobronchial epithelial cells. Mol Pharmacol. 2000 Sep;58(3):483-90.
• [95] Integrating multiple omics to unravel mechanisms of Cyclosporin A induced hepatotoxicity in vitro. Toxicol In Vitro. 2015 Apr;29(3):489-501.
• [96] Time dependent impact of copper oxide nanomaterials on the expression of genes associated with oxidative stress, metal binding, inflammation and mucus secretion in single and co-culture intestinal in vitro models. Toxicol In Vitro. 2021 Aug;74:105161. doi: 10.1016/j.tiv.2021.105161. Epub 2021 Apr 9.
• [97] Differential expression of microRNAs and their predicted targets in renal cells exposed to amphotericin B and its complex with copper (II) ions. Toxicol Mech Methods. 2017 Sep;27(7):537-543. doi: 10.1080/15376516.2017.1333554. Epub 2017 Jun 8.
• [98] Inorganic arsenic exposure promotes malignant progression by HDAC6-mediated down-regulation of HTRA1. J Appl Toxicol. 2023 Aug;43(8):1214-1224. doi: 10.1002/jat.4457. Epub 2023 Mar 11.
• [99] Gene expression profile induced by BCNU in human glioma cell lines with differential MGMT expression. J Neurooncol. 2005 Jul;73(3):189-98.
• [100] Selenium and vitamin E: cell type- and intervention-specific tissue effects in prostate cancer. J Natl Cancer Inst. 2009 Mar 4;101(5):306-20.
• [101] Comparison of HepG2 and HepaRG by whole-genome gene expression analysis for the purpose of chemical hazard identification. Toxicol Sci. 2010 May;115(1):66-79.
• [102] Gene Expression Regulation and Pathway Analysis After Valproic Acid and Carbamazepine Exposure in a Human Embryonic Stem Cell-Based Neurodevelopmental Toxicity Assay. Toxicol Sci. 2015 Aug;146(2):311-20. doi: 10.1093/toxsci/kfv094. Epub 2015 May 15.
• [103] Estradiol and selective estrogen receptor modulators differentially regulate target genes with estrogen receptors alpha and beta. Mol Biol Cell. 2004 Mar;15(3):1262-72. doi: 10.1091/mbc.e03-06-0360. Epub 2003 Dec 29.
• [104] Gene expression profiling of 30 cancer cell lines predicts resistance towards 11 anticancer drugs at clinically achieved concentrations. Int J Cancer. 2006 Apr 1;118(7):1699-712. doi: 10.1002/ijc.21570.
• [105] Transcriptional signature of human macrophages exposed to the environmental contaminant benzo(a)pyrene. Toxicol Sci. 2010 Apr;114(2):247-59.
• [106] Characterization of human short chain dehydrogenase/reductase SDR16C family members related to retinol dehydrogenase 10. Chem Biol Interact. 2017 Oct 1;276:88-94. doi: 10.1016/j.cbi.2016.10.019. Epub 2016 Oct 25.
• [107] Large-scale in silico and microarray-based identification of direct 1,25-dihydroxyvitamin D3 target genes. Mol Endocrinol. 2005 Nov;19(11):2685-95.
• [108] From transient transcriptome responses to disturbed neurodevelopment: role of histone acetylation and methylation as epigenetic switch between reversible and irreversible drug effects. Arch Toxicol. 2014 Jul;88(7):1451-68.
• [109] Physiological and toxicological transcriptome changes in HepG2 cells exposed to copper. Physiol Genomics. 2009 Aug 7;38(3):386-401.
• [110] Blood transcript immune signatures distinguish a subset of people with elevated serum ALT from others given acetaminophen. Clin Pharmacol Ther. 2016 Apr;99(4):432-41.
• [111] Air pollution and DNA methylation alterations in lung cancer: A systematic and comparative study. Oncotarget. 2017 Jan 3;8(1):1369-1391. doi: 10.18632/oncotarget.13622.
• [112] Transcriptional profiling of lactic acid treated reconstructed human epidermis reveals pathways underlying stinging and itch. Toxicol In Vitro. 2019 Jun;57:164-173.
• [113] Cannabidiol-induced transcriptomic changes and cellular senescence in human Sertoli cells. Toxicol Sci. 2023 Feb 17;191(2):227-238. doi: 10.1093/toxsci/kfac131.
• [114] DNA demethylation by 5-aza-2-deoxycytidine treatment abrogates 17 beta-estradiol-induced cell growth and restores expression of DNA repair genes in human breast cancer cells. Cancer Lett. 2012 Mar;316(1):62-9. doi: 10.1016/j.canlet.2011.10.022. Epub 2011 Oct 23.
• [115] Chronic exposure to arsenic causes increased cell survival, DNA damage, and increased expression of mitochondrial transcription factor A (mtTFA) in human prostate epithelial cells. Chem Res Toxicol. 2011 Mar 21;24(3):340-9. doi: 10.1021/tx1003112. Epub 2011 Jan 14.
• [116] Mitochondrial reactive oxygen species are scavenged by Cockayne syndrome B protein in human fibroblasts without nuclear DNA damage. Proc Natl Acad Sci U S A. 2014 Sep 16;111(37):13487-92. doi: 10.1073/pnas.1414135111. Epub 2014 Aug 18.
• [117] The endoperoxide ascaridol shows strong differential cytotoxicity in nucleotide excision repair-deficient cells. Toxicol Appl Pharmacol. 2012 Mar 15;259(3):302-10. doi: 10.1016/j.taap.2012.01.006. Epub 2012 Jan 17.
• [118] Late activation of stress-activated protein kinases/c-Jun N-terminal kinases triggered by cisplatin-induced DNA damage in repair-defective cells. J Biol Chem. 2011 Apr 15;286(15):12991-3001. doi: 10.1074/jbc.M110.190645. Epub 2011 Feb 15.
• [119] Cannabidiol enhances cytotoxicity of anti-cancer drugs in human head and neck squamous cell carcinoma. Sci Rep. 2020 Nov 26;10(1):20622. doi: 10.1038/s41598-020-77674-y.
• [120] Evidence of securin-mediated resistance to gefitinib-induced apoptosis in human cancer cells. Chem Biol Interact. 2013 Apr 25;203(2):412-22. doi: 10.1016/j.cbi.2013.03.011. Epub 2013 Mar 22.
• [121] Cigarette smoke and asbestos activate poly-ADP-ribose polymerase in alveolar epithelial cells. J Investig Med. 2001 Jan;49(1):68-76. doi: 10.2310/6650.2001.34092.
• [122] Apoptotic signaling pathways induced by nitric oxide in human lymphoblastoid cells expressing wild-type or mutant p53. Cancer Res. 2004 May 1;64(9):3022-9. doi: 10.1158/0008-5472.can-03-1880.
• [123] The antidepressants imipramine, clomipramine, and citalopram induce apoptosis in human acute myeloid leukemia HL-60 cells via caspase-3 activation. J Biochem Mol Toxicol. 1999;13(6):338-47. doi: 10.1002/(sici)1099-0461(1999)13:6<338::aid-jbt8>3.0.co;2-7.
• [124] Ciprofloxacin mediated cell growth inhibition, S/G2-M cell cycle arrest, and apoptosis in a human transitional cell carcinoma of the bladder cell line. Clin Cancer Res. 2000 Mar;6(3):891-900.
• [125] Investigation of molecular mechanisms underlying the antiproliferative effects of colchicine against PC3 prostate cancer cells. Toxicol In Vitro. 2021 Jun;73:105138. doi: 10.1016/j.tiv.2021.105138. Epub 2021 Mar 6.
• [126] Sulindac enhances adenoviral vector expressing mda-7/IL-24-mediated apoptosis in human lung cancer. Mol Cancer Ther. 2005 Feb;4(2):291-304.
• [127] Methotrexate induces poly(ADP-ribose) polymerase-dependent, caspase 3-independent apoptosis in subsets of proliferating CD4+ T cells. Clin Exp Immunol. 2007 May;148(2):288-95. doi: 10.1111/j.1365-2249.2007.03335.x. Epub 2007 Feb 7.
• [128] Temozolomide induces activation of Wnt/-catenin signaling in glioma cells via PI3K/Akt pathway: implications in glioma therapy. Cell Biol Toxicol. 2020 Jun;36(3):273-278. doi: 10.1007/s10565-019-09502-7. Epub 2019 Nov 22.
• [129] Activation of AIFM2 enhances apoptosis of human lung cancer cells undergoing toxicological stress. Toxicol Lett. 2016 Sep 6;258:227-236.
• [130] Drinking-water arsenic exposure modulates gene expression in human lymphocytes from a U.S. population. Environ Health Perspect. 2008 Apr;116(4):524-31. doi: 10.1289/ehp.10861.
• [131] Multiple microRNAs function as self-protective modules in acetaminophen-induced hepatotoxicity in humans. Arch Toxicol. 2018 Feb;92(2):845-858.
• [132] 17-Estradiol Activates HSF1 via MAPK Signaling in ER-Positive Breast Cancer Cells. Cancers (Basel). 2019 Oct 11;11(10):1533. doi: 10.3390/cancers11101533.
• [133] Transcriptome and DNA methylome dynamics during triclosan-induced cardiomyocyte differentiation toxicity. Stem Cells Int. 2018 Oct 29;2018:8608327.
• [134] Bromodomain-containing protein 4 (BRD4) regulates RNA polymerase II serine 2 phosphorylation in human CD4+ T cells. J Biol Chem. 2012 Dec 14;287(51):43137-55.
• [135] THC exposure of human iPSC neurons impacts genes associated with neuropsychiatric disorders. Transl Psychiatry. 2018 Apr 25;8(1):89. doi: 10.1038/s41398-018-0137-3.
• [136] The exosome-like vesicles derived from androgen exposed-prostate stromal cells promote epithelial cells proliferation and epithelial-mesenchymal transition. Toxicol Appl Pharmacol. 2021 Jan 15;411:115384. doi: 10.1016/j.taap.2020.115384. Epub 2020 Dec 25.
• [137] Human embryonic stem cell-derived test systems for developmental neurotoxicity: a transcriptomics approach. Arch Toxicol. 2013 Jan;87(1):123-43.
• [138] Quantitative proteomics reveals a broad-spectrum antiviral property of ivermectin, benefiting for COVID-19 treatment. J Cell Physiol. 2021 Apr;236(4):2959-2975. doi: 10.1002/jcp.30055. Epub 2020 Sep 22.
• [139] Linalool is a PPARalpha ligand that reduces plasma TG levels and rewires the hepatic transcriptome and plasma metabolome. J Lipid Res. 2014 Jun;55(6):1098-110.
• [140] Growth inhibition of ovarian tumor-initiating cells by niclosamide. Mol Cancer Ther. 2012 Aug;11(8):1703-12.
• [141] Metabolomics of oxidative stress: Nrf2 independent depletion of NAD or increases of sugar alcohols. Toxicol Appl Pharmacol. 2022 May 1;442:115949. doi: 10.1016/j.taap.2022.115949. Epub 2022 Feb 25.
• [142] Comparison of phenotypic and transcriptomic effects of false-positive genotoxins, true genotoxins and non-genotoxins using HepG2 cells. Mutagenesis. 2011 Sep;26(5):593-604.
• [143] Comparative gene expression analysis of a chronic myelogenous leukemia cell line resistant to cyclophosphamide using oligonucleotide arrays and response to tyrosine kinase inhibitors. Leuk Res. 2007 Nov;31(11):1511-20.
• [144] Survival of retinal pigment epithelium after exposure to prolonged oxidative injury: a detailed gene expression and cellular analysis. Invest Ophthalmol Vis Sci. 2004 Oct;45(10):3767-77.
• [145] A systems biology understanding of the synergistic effects of arsenic sulfide and Imatinib in BCR/ABL-associated leukemia. Proc Natl Acad Sci U S A. 2009 Mar 3;106(9):3378-83.
• [146] The enzymatic activity of human aldehyde dehydrogenases 1A2 and 2 (ALDH1A2 and ALDH2) is detected by Aldefluor, inhibited by diethylaminobenzaldehyde and has significant effects on cell proliferation and drug resistance. Chem Biol Interact. 2012 Jan 5;195(1):52-60.
• [147] Cannabidiol Displays Proteomic Similarities to Antipsychotics in Cuprizone-Exposed Human Oligodendrocytic Cell Line MO3.13. Front Mol Neurosci. 2021 May 28;14:673144. doi: 10.3389/fnmol.2021.673144. eCollection 2021.
• [148] Changes in gene expression profiles of multiple myeloma cells induced by arsenic trioxide (ATO): possible mechanisms to explain ATO resistance in vivo. Br J Haematol. 2005 Mar;128(5):636-44.
• [149] Low doses of cisplatin induce gene alterations, cell cycle arrest, and apoptosis in human promyelocytic leukemia cells. Biomark Insights. 2016 Aug 24;11:113-21.
• [150] Pharmacogenomic analysis of acute promyelocytic leukemia cells highlights CYP26 cytochrome metabolism in differential all-trans retinoic acid sensitivity. Blood. 2007 May 15;109(10):4450-60.
• [151] Expression profile analysis of human peripheral blood mononuclear cells in response to aspirin. Arch Immunol Ther Exp (Warsz). 2005 Mar-Apr;53(2):151-8.
• [152] Effects of 1alpha,25 dihydroxyvitamin D3 and testosterone on miRNA and mRNA expression in LNCaP cells. Mol Cancer. 2011 May 18;10:58.
• [153] Stem cell transcriptome responses and corresponding biomarkers that indicate the transition from adaptive responses to cytotoxicity. Chem Res Toxicol. 2017 Apr 17;30(4):905-922.
• [154] Folate deficiency in normal human fibroblasts leads to altered expression of genes primarily linked to cell signaling, the cytoskeleton and extracellular matrix. J Nutr Biochem. 2007 Aug;18(8):541-52. doi: 10.1016/j.jnutbio.2006.11.002. Epub 2007 Feb 22.